Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis

Ayers Gilberth Ivano Kalaij; Valerie Josephine Dirjayanto; Syarif Maulana Yusuf; Erni Juwita Nelwan

doi:10.13181/mji.oa.215559

Authors

Ayers Gilberth Ivano Kalaij Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia https://orcid.org/0000-0003-2860-5055
Valerie Josephine Dirjayanto Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Syarif Maulana Yusuf Infectious Disease and Immunology Research Center, Indonesia Medical and Education Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Erni Juwita Nelwan Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia https://orcid.org/0000-0003-4064-5412

DOI:

https://doi.org/10.13181/mji.oa.215559

Keywords:

adenovirus vaccine, COVID-19, immunogenicity, safety, SARS-CoV-2

Abstract

BACKGROUND Despite various research on vaccine development, severe acute respiratory syndrome coronavirus 2 infection continues to spread. Thus, developing a more effective vaccine for production and clinical efficacy is still in high demand. This review aimed to assess the immunogenicity and safety of adenovirus-based vector vaccine (Ad-vaccines) including Ad5-vectored, ChAdOx1 nCoV-19, rAd26-S or rAd5-S, and Ad26.COV2.S as the promising solutions for COVID-19.

METHODS We conducted a systematic review and meta analysis of clinical trials based on the preferred reporting items for systematic reviews and meta-analyses guidelines through PubMed, Scopus, Cochrane, and EBSCOhost until August 17, 2021. We implemented inclusion and exclusion criteria and assessed the studies using OHAT risk of bias rating tool for human and animal studies. Pooled estimates of odds ratio (OR) were analyzed using fixed-effect model.

RESULTS This systematic review yielded 12 clinical studies with a total of 75,105 subjects. Although the studies were heterogeneous, this meta-analysis showed that Ad-vaccine significantly increased protection and immune response against COVID-19 with a pooled efficacy of 84.68% compared to placebo (p<0.00001). Forest plot also indicated that Ad-vaccine conferred protection against moderate to severe COVID-19 with a pooled OR of 0.26 (p<0.00001). Ad-vaccine had also shown a good safety profile with local site pain and fever as the most common side effects.

CONCLUSIONS Ad-vaccine had shown a good immunogenicity for COVID-19 with a good pooled efficacy and was proven safe for COVID-19 patients.

Downloads

Download data is not yet available.

References

Centers for Disease Control and Prevention (CDC). COVID-19 and your health [Internet]. Centers for Disease Control and Prevention (CDC); 2020 [cited 2021 Jan 29]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/ different-vaccines/mrna.html.

UK Health Centre. Advantages & disadvantages of inactivated vaccines [Internet]. UK Health Centre; 2021 [cited 2021 Jan 29]. Available from: https://www.healthcentre.org.uk/vaccine/advantages-disadvantages-inactivated-vaccines.html.

Saadeldin MK, Abdel-Aziz AK, Abdellatif A. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Med Hypotheses. 2021;146:110365. https://doi.org/10.1016/j.mehy.2020.110365

Garofalo M, Staniszewska M, Salmaso S, Caliceti P, Pancer KW, Wieczorek M, et al. Prospects of replication-deficient adenovirus based vaccine development against SARS-CoV-2. Vaccines. 2020;8(2):293. https://doi.org/10.3390/vaccines8020293

Li JX, Hou LH, Meng FY, Wu SP, Hu YM, Liang Q, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5(3):e324-34. https://doi.org/10.1016/S2214-109X(16)30367-9

Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081. https://doi.org/10.1038/s41467-020-17972-1

National Toxicology Program, U.S. Department of Health and Human Services. Handbook for conducting systematic reviews for health effects evaluations [Internet]. National Toxicology Program, U.S. Department of Health and Human Services; 2021 [cited 2021 Sep 2]. Available from: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook/index.html.

Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-63. https://doi.org/10.1111/j.0006-341X.2000.00455.x

Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-88. https://doi.org/10.1016/S0140-6736(20)31605-6

Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-54. https://doi.org/10.1016/S0140-6736(20)31208-3

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78. https://doi.org/10.1016/S0140-6736(20)31604-4

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97. https://doi.org/10.1016/S0140-6736(20)31866-3

Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 2021;325(15):1535-44. https://doi.org/10.1001/jama.2021.3645

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201. https://doi.org/10.1056/NEJMoa2101544

Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26. COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824-35. https://doi.org/10.1056/NEJMoa2034201

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979-93. https://doi.org/10.1016/S0140-6736(20)32466-1

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885-98. https://doi.org/10.1056/NEJMoa2102214

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81. https://doi.org/10.1016/S0140-6736(21)00234-8

Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270-8. https://doi.org/10.1038/s41591-020-01194-5

Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351-62. https://doi.org/10.1016/S0140-6736(21)00628-0

Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081. https://doi.org/10.1038/s41467-020-17972-1

Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169-84.e13. https://doi.org/10.1016/j.cell.2020.08.026

Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Vaccine X. 2020;6:100076. https://doi.org/10.1016/j.jvacx.2020.100076

Graham SP, McLean RK, Spencer AJ, Belij-Rammerstorfer S, Wright D, Ulaszewska M, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. npj Vaccines. 2020;5(1):69. https://doi.org/10.1038/s41541-020-00221-3

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-35. https://doi.org/10.1038/s41423-020-0402-2

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613-20. https://doi.org/10.1038/s41423-020-0400-4

Walls AC, Xiong X, Park YJ, Tortorici MA, Snijder J, Quispe J, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell. 2019;176(5):1026-39.e15. https://doi.org/10.1016/j.cell.2018.12.028

Spencer JP, Pawlowski RH, Thomas S. Vaccine adverse events: separating myth from reality. Am Fam Physician. 2017;95(12):786-94.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158-68.e14. https://doi.org/10.1016/j.cell.2020.08.017